Alkeon Capital Management
ANRO icon

Alkeon Capital Management’s Alto Neuroscience ANRO Stock Holding History

Alkeon Capital Management’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.11M Sell
227,101
-250,000
-52% -$4.63M 0.01% 99
2025
Q4 		$8.49M Hold
477,101
– – 0.01% 110
2025
Q3 		$1.92M Hold
477,101
– – ﹤0.01% 106
2025
Q2 		$1.05M Hold
477,101
– – ﹤0.01% 103
2025
Q1 		$1.03M Hold
477,101
– – ﹤0.01% 105
2024
Q4 		$2.02M Sell
477,101
-457,803
-49% -$2.86M ﹤0.01% 93
2024
Q3 		$10.7M Hold
934,904
– – 0.02% 88
2024
Q2 		$9.99M Buy
+934,904
New +$12.2M 0.02% 96

Other funds holding ANRO

AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Alkeon Capital Management's ANRO Position: Q1 2026 in Review

Alkeon Capital Management reduced its Alto Neuroscience (ANRO) stake by 52% in Q1 2026, selling an estimated $4.63M and leaving 227,101 shares worth $5.11M. The position accounts for 0.01% of the portfolio, ranked #99.

Alkeon Capital Management first reported a position in ANRO in Q2 2024 and has held it in 8 quarters since. The position peaked at $10.7M in Q3 2024. 110 funds tracked by Wall St. Rank hold ANRO as of Q1 2026.

  • Alkeon Capital Management held 227,101 shares of Alto Neuroscience worth $5.11M as of Q1 2026.
  • Alkeon Capital Management sold 250,000 Alto Neuroscience shares in Q1 2026, an estimated $4.63M.
  • Alto Neuroscience made up 0.01% of Alkeon Capital Management's portfolio in Q1 2026, its #99 holding.
  • Alkeon Capital Management first reported a position in Alto Neuroscience in Q2 2024 and has held it in 8 quarters since.
  • Alkeon Capital Management's Alto Neuroscience position peaked at $10.7M in Q3 2024.
  • 110 funds tracked by Wall St. Rank held Alto Neuroscience as of Q1 2026.

Based on Alkeon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.